Inicio › Leucemia linfocítica crónica › Tennessee
Ensayos clínicos de Leucemia linfocítica crónica en Tennessee
17 estudios sobre Leucemia linfocítica crónica buscan participantes en Tennessee.
Ciudades en Tennessee
Texto oficial del estudio (inglés)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Ballad Health Cancer Care - Kingsport, Kingsport
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Tennessee Oncology Greco Hainsworth Centers For Research Chattanooga, Chattanooga
- Tennessee Oncology, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Tennessee Oncology, Pllc Nashville, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Tennessee Oncology-Chattanooga ( Site 0045), Chattanooga
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- SCRI Oncology Partners, Nashville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221500Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
ReclutandoFase 3
Edades de 65 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT07321652Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- SCRI Oncology Partners, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 ago 2026 · NCT07516093Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- SCRI Oncology Partners, Nashville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07520006A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Sarah Cannon Research Institute SCRI, Nashville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 may 2026 · NCT06588478The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
ReclutandoFase 1/2
Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT04830137A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Tennessee Oncology, Nashville
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Tennessee Oncology, Nashville
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662HPC Offered for PRESERVE Expansion
- Tristar Centennial Medical Center, Nashville
ReclutandoEstudio observacional
Edades de 12 a 80 · Todos los sexos · Actualizado el 28 ago 2025 · NCT07145411De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.